Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Medpace (MEDP)

Medpace Q1 revenue rises 17.7% to $511.0 million; diluted EPS $3.20 vs. $2.27

Positive Impact 3 of 5 earnings Written later

Medpace reported first-quarter 2024 revenue of $511.0 million, up 17.7% from a year earlier, and GAAP net income of $102.6 million, or $3.20 per diluted share, versus $2.27 a year earlier. The company also forecast full-year 2024 revenue of $2.150 billion to $2.200 billion and GAAP diluted EPS of $10.79 to $11.47, and reported no share repurchases in the quarter.

Key points

  • Q1 2024 revenue $511.0 million, up 17.7% from $434.1 million; backlog rose 18.2% to $2,907.1 million.
  • Q1 2024 GAAP net income $102.6 million, or $3.20 per diluted share, vs. $72.9 million, or $2.27, in Q1 2023; EBITDA rose 24.6% to $115.7 million.
  • 2024 guidance: revenue $2.150 billion to $2.200 billion; GAAP net income $347.0 million to $369.0 million.
  • No share repurchases in Q1 2024; $308.8 million remained under the authorized program at March 31, 2024.

The filing

CompanyMedpace (MEDP)
Form8-K, current report
Filed with the SECApr 22, 2024, 4:15 PM ET
Accession number0001668397-24-000089

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 22, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.